	US 11,970,538 B2
	Multispecific binding constructs against checkpoint molecules and uses thereof
Bing Gong, Brighton, MA (US); Rachel Rennard, Stoneham, MA (US); Amanda Frank Oliphant, Boston, MA (US); Cheuk Lun Leung, Quincy, MA (US); Benjamin Jacob Wolf, Seattle, WA (US); Ugur Eskiocak, Somerville, MA (US); Pearl Bakhru, Ashland, MA (US); and Diana I. Albu, Windham, NH (US)
Assigned to COMPASS THERAPEUTICS LLC, Brighton, MA (US)
Filed by Compass Therapeutics LLC, Brighton, MA (US)
Filed on May 20, 2021, as Appl. No. 17/325,268.
Application 17/325,268 is a division of application No. 16/682,756, filed on Nov. 13, 2019, granted, now 11,046,769.
Claims priority of provisional application 62/931,478, filed on Nov. 6, 2019.
Claims priority of provisional application 62/898,991, filed on Sep. 11, 2019.
Claims priority of provisional application 62/855,580, filed on May 31, 2019.
Claims priority of provisional application 62/760,801, filed on Nov. 13, 2018.
Prior Publication US 2021/0284736 A1, Sep. 16, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

23 Claims

1. An antibody or antigen-binding fragment thereof that binds PD-1 and comprises:

(a) a heavy chain variable region comprising (i) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 70 (FTFX₁X₂YAX₃X₄, wherein X₁=S, R, G, or N; X₂=D, S, N, A, R, or G; X₃=M or L; X₄=S, L, or N); (ii) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 71; and (iii) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 72 (ARGLDFIVGX₅TGNDY, wherein X₅=A, Y, or R); and

(b) a light chain variable region comprising: (i) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 9; (ii) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 5; and (iii) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 10.